BACKGROUND: Germline BRCA1/2mut breast cancer (BC) represents ~5% of all BC. Historically, chemotherapy (CT) and/or endocrine therapy was commonly used in these pts, but targeted treatments (poly ADP-ribose polymerase inhibitors [PARPi]) have become recently available. This study assessed real-world pt demographics, clinical characteristics, and treatment patterns across different lines of therapy (LOT) among US pts with gBRCA1/2mut HER2– ABC.
MATERIALS AND METHODS: Oncologists retrospectively reviewed charts (July-Oct 2019) of randomly selected pts ≥18 yrs, with HER2 gBRCA1/2mut ABC who received ≥1 cytotoxic CT regimen(s) for ABC between Jan 2013-Apr 2018. Pt demographics/clinical characteristics were measured at ABC diagnosis. Pt characteristics and regimens for the 1st 3 LOT for ABC were descriptively summarized.
RESULTS: 177 pts were included: 99.4% were female, 78.5% were white, 11.3% had Ashkenazi Jewish descent. No known family history (FH) of BRCA-related cancer(s) was reported by 27.7% of pts. Median age was 58.0 yrs. 62.1% had advanced triple-negative BC (TNBC) and 37.9% had hormone receptor (HR)+/HER2– ABC. Common comorbidities in 64.4% of pts included hypertension (37.3%), depression (25.4%), and diabetes (15.8%). Frequency of treatments varied by LOT (Table 1). Treatment patterns by different years will be presented.
CONCLUSIONS: In gBRCA1/2mut HER2- ABC pts, comorbidities were commonly reported, and a significant proportion of the pts had no known FH of BRCA-related cancer(s). Frequency of treatments varied by LOT. Testing all pts with ABC for gBRCA1/2mut should be considered. Pt characteristics, including comorbidities, should be considered when evaluating treatment options, since targeted treatments with improved efficacy and favorable pt reported outcomes are now available.
